董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rajeev Shah | 男 | Director | 41 | 未披露 | 未持股 | 2018-06-05 |
| Eric Aguiar | 男 | Director | 56 | 未披露 | 未持股 | 2018-06-05 |
| Jonathan C. Fox | 男 | Director, President and Chief Medical Officer | 61 | 170.76万美元 | 未持股 | 2018-06-05 |
| Neil Kumar | 男 | Chief Executive Officer and Director | 39 | 14.04万美元 | 未持股 | 2018-06-05 |
| Ali Satvat | 男 | Director | 40 | 未披露 | 未持股 | 2018-06-05 |
| Hoyoung Huh | 男 | Director | 48 | 未披露 | 未持股 | 2018-06-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan C. Fox | 男 | Director, President and Chief Medical Officer | 61 | 170.76万美元 | 未持股 | 2018-06-05 |
| Neil Kumar | 男 | Chief Executive Officer and Director | 39 | 14.04万美元 | 未持股 | 2018-06-05 |
| Uma Sinha | 女 | Chief Scientific Officer | 61 | 57.33万美元 | 未持股 | 2018-06-05 |
| Christine Siu | 女 | Chief Financial Officer | 41 | 未披露 | 未持股 | 2018-06-05 |
董事简历
中英对照 | 中文 | 英文- Rajeev Shah
-
Rajeev Shah，2013年9月以来，他一直担任我们董事会的成员。他是RA Capital Management公司（一个投资咨询公司，一直在投资于卫生保健公司）的合伙人和投资组合经理（2002年以来）。2004年加入RA Capital公司之前，他曾担任Altus Pharmaceuticals公司的高级项目负责人。他持有Cornell University的化学学士学位。
Rajeev Shah has served as a member of our Board of Directors since March 2017. Mr. Shah has been a managing partner at RA Capital Management, L.P., a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics, since 2004. Mr. Shah is also a member of the board of directors of Eidos Therapeutics, Inc., Kala Pharmaceuticals, Inc., Satsuma Pharmaceuticals, Inc.,. and Black Diamond Therapeutics, Inc., each a public biopharmaceutical company. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals, Inc. from June 2015 through April 2018 and Ra Pharmaceuticals, Inc. from July 2015 through April 2020 both public pharmaceutical companies. Mr. Shah received a B.A. in Chemistry from Cornell University. - Rajeev Shah，2013年9月以来，他一直担任我们董事会的成员。他是RA Capital Management公司（一个投资咨询公司，一直在投资于卫生保健公司）的合伙人和投资组合经理（2002年以来）。2004年加入RA Capital公司之前，他曾担任Altus Pharmaceuticals公司的高级项目负责人。他持有Cornell University的化学学士学位。
- Rajeev Shah has served as a member of our Board of Directors since March 2017. Mr. Shah has been a managing partner at RA Capital Management, L.P., a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics, since 2004. Mr. Shah is also a member of the board of directors of Eidos Therapeutics, Inc., Kala Pharmaceuticals, Inc., Satsuma Pharmaceuticals, Inc.,. and Black Diamond Therapeutics, Inc., each a public biopharmaceutical company. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals, Inc. from June 2015 through April 2018 and Ra Pharmaceuticals, Inc. from July 2015 through April 2020 both public pharmaceutical companies. Mr. Shah received a B.A. in Chemistry from Cornell University.
- Eric Aguiar
-
Eric Aguiar获得医学博士学位，他从2010年9月开始一直担任Invitae Corporation董事。他从2007年开始一直担任风险投资公司Thomas, McNerney & Partners的合伙人。加入该公司前，从2001年到2007年，他担任专注于医疗保健行业的风险投资公司健康保健投资（HealthCare Ventures）的常务董事。从1998年到2000年，Aguiar博士担任专注于基因送递与基因调控的生物制药公司Genovo, Inc.的首席执行官兼董事。在这之前，Aguiar博士担任一家公众所有的生物制药公司Amarin Pharmaceuticals的董事，并担任多家私人公司的董事，其中包括生命科学行业的公司。他是塔夫斯医学院Tufts School of Medicine的监事会监事，并担任美国对外关系委员会（Council on Foreign Relations）的委员。他在哈佛大学医学院（Harvard Medical School）以优异成绩获得医学博士学位；在康乃尔大学（Cornell University）获得艺术与科学文学学士学位。Aguiar博士还是鲁思研究员，并是特许财务分析师。
Eric Aguiar,has served as a member of board of directors since December 2020 and as Lead Independent Director since March 2025. Dr. Aguiar has been a partner at Aisling Capital, a healthcare-focused venture fund, since January 2016. Prior to Aisling Capital, from October 2007 to December 2015, he was a partner at Thomas, McNerney and Partners, a healthcare venture capital and growth equity fund. From 2001 to 2007, Dr. Aguiar was Managing Director of HealthCare Ventures, a healthcare-focused venture capital firm. Previously, Dr. Aguiar was Chief Executive Officer of Genovo, Inc., a privately held biopharmaceutical company, from 1998 to 2000. Dr. Aguiar has served on the board of directors of BridgeBio Pharma, Inc. (Nasdaq: BBIO) since June 2019, a public pharmaceutical company. Dr. Aguiar previously served on the boards of directors of numerous public life sciences companies, including Biohaven Pharmaceuticals, Inc. (Nasdaq: BHVN), which was acquired by Pfizer, Inc. in October 2022, and Eidos Therapeutics, Inc. (Nasdaq: EIDX) (prior to its merger with BridgeBio Pharma, Inc. (Nasdaq: BBIO) in January 2021), Invitae Corporation (Nasdaq: NVTA), and Amarin Corporation plc (NASDAQ: AMRN). Dr. Aguiar also serves on the board of directors of privately-held Garuda Therapeutics, Inc. as well as GondolaBio LLC, and previously served on the board of directors of Oriel Therapeutics, Inc. (prior to its acquisition by Novartis AG (NYSE: NVS)). Dr. Aguiar is a member of the Council on Foreign Relations. Dr. Aguiar holds a B.A. in College Scholar from Cornell University and an M.D. from Harvard Medical School, and is a Chartered Financial Analyst. - Eric Aguiar获得医学博士学位，他从2010年9月开始一直担任Invitae Corporation董事。他从2007年开始一直担任风险投资公司Thomas, McNerney & Partners的合伙人。加入该公司前，从2001年到2007年，他担任专注于医疗保健行业的风险投资公司健康保健投资（HealthCare Ventures）的常务董事。从1998年到2000年，Aguiar博士担任专注于基因送递与基因调控的生物制药公司Genovo, Inc.的首席执行官兼董事。在这之前，Aguiar博士担任一家公众所有的生物制药公司Amarin Pharmaceuticals的董事，并担任多家私人公司的董事，其中包括生命科学行业的公司。他是塔夫斯医学院Tufts School of Medicine的监事会监事，并担任美国对外关系委员会（Council on Foreign Relations）的委员。他在哈佛大学医学院（Harvard Medical School）以优异成绩获得医学博士学位；在康乃尔大学（Cornell University）获得艺术与科学文学学士学位。Aguiar博士还是鲁思研究员，并是特许财务分析师。
- Eric Aguiar,has served as a member of board of directors since December 2020 and as Lead Independent Director since March 2025. Dr. Aguiar has been a partner at Aisling Capital, a healthcare-focused venture fund, since January 2016. Prior to Aisling Capital, from October 2007 to December 2015, he was a partner at Thomas, McNerney and Partners, a healthcare venture capital and growth equity fund. From 2001 to 2007, Dr. Aguiar was Managing Director of HealthCare Ventures, a healthcare-focused venture capital firm. Previously, Dr. Aguiar was Chief Executive Officer of Genovo, Inc., a privately held biopharmaceutical company, from 1998 to 2000. Dr. Aguiar has served on the board of directors of BridgeBio Pharma, Inc. (Nasdaq: BBIO) since June 2019, a public pharmaceutical company. Dr. Aguiar previously served on the boards of directors of numerous public life sciences companies, including Biohaven Pharmaceuticals, Inc. (Nasdaq: BHVN), which was acquired by Pfizer, Inc. in October 2022, and Eidos Therapeutics, Inc. (Nasdaq: EIDX) (prior to its merger with BridgeBio Pharma, Inc. (Nasdaq: BBIO) in January 2021), Invitae Corporation (Nasdaq: NVTA), and Amarin Corporation plc (NASDAQ: AMRN). Dr. Aguiar also serves on the board of directors of privately-held Garuda Therapeutics, Inc. as well as GondolaBio LLC, and previously served on the board of directors of Oriel Therapeutics, Inc. (prior to its acquisition by Novartis AG (NYSE: NVS)). Dr. Aguiar is a member of the Council on Foreign Relations. Dr. Aguiar holds a B.A. in College Scholar from Cornell University and an M.D. from Harvard Medical School, and is a Chartered Financial Analyst.
- Jonathan C. Fox
-
Jonathan C. Fox，2013年3月起担任本公司首席医疗官。此前，于2006年11月-2012年7月期间，担任阿斯利康（AstraZeneca）的临床发展副总裁；此前，2004年1月-2006年11月期间担任AstraZeneca执行董事，负责心血管疾病、代谢及胃肠道的产品组合。此前，他曾在Merck & Co。担任临床心血管研究高级总监，以及GlaxoSmithKline plc。担任临床药理总监。他曾是Pennsylvania大学医学院20年的临床医学教授；此前曾监督血管生物学基础研究实验室。他目前在Stanford大学心血管病研究所担任顾问教授，担任洛杉矶California大学创新、技术和联盟顾问；以及是PA州温尼伍德Lankenau医学研究研究所的一个长期受托人。他还曾在美国FDA（Food and Drug Administration）心血管和肾脏药物产品咨询委员会担任四年的行业代表。他持有Chicago大学的学士、博士和医学硕士学位。以及完成了Duke大学的内科和心脏科研究生课程。
Jonathan C. Fox has served as our President and Chief Medical Officer since October 2016. Dr. Fox has served as the TA lead of cardiovascular and renal diseases at BridgeBio Pharma, LLC since October 2016. Prior to that, from March 2013 to September 2016 Dr. Fox served as the chief medical officer of MyoKardia, Inc. and as a senior advisor from October 2016 to March 2017. He worked as a consultant at Nigel-Montgomery, LLC from August 2012 to March 2013 and held various senior positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca LP from 1998 to 2012. He was on the faculty of the University of Pennsylvania School of Medicine from 1993 to 2013. He currently holds an adjunct faculty position at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in medicine and pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases, and is a Fellow of the American College of Cardiology. - Jonathan C. Fox，2013年3月起担任本公司首席医疗官。此前，于2006年11月-2012年7月期间，担任阿斯利康（AstraZeneca）的临床发展副总裁；此前，2004年1月-2006年11月期间担任AstraZeneca执行董事，负责心血管疾病、代谢及胃肠道的产品组合。此前，他曾在Merck & Co。担任临床心血管研究高级总监，以及GlaxoSmithKline plc。担任临床药理总监。他曾是Pennsylvania大学医学院20年的临床医学教授；此前曾监督血管生物学基础研究实验室。他目前在Stanford大学心血管病研究所担任顾问教授，担任洛杉矶California大学创新、技术和联盟顾问；以及是PA州温尼伍德Lankenau医学研究研究所的一个长期受托人。他还曾在美国FDA（Food and Drug Administration）心血管和肾脏药物产品咨询委员会担任四年的行业代表。他持有Chicago大学的学士、博士和医学硕士学位。以及完成了Duke大学的内科和心脏科研究生课程。
- Jonathan C. Fox has served as our President and Chief Medical Officer since October 2016. Dr. Fox has served as the TA lead of cardiovascular and renal diseases at BridgeBio Pharma, LLC since October 2016. Prior to that, from March 2013 to September 2016 Dr. Fox served as the chief medical officer of MyoKardia, Inc. and as a senior advisor from October 2016 to March 2017. He worked as a consultant at Nigel-Montgomery, LLC from August 2012 to March 2013 and held various senior positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca LP from 1998 to 2012. He was on the faculty of the University of Pennsylvania School of Medicine from 1993 to 2013. He currently holds an adjunct faculty position at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in medicine and pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases, and is a Fellow of the American College of Cardiology.
- Neil Kumar
-
Neil Kumar是我们的联合创始人，自2015年4月起担任我们的首席执行官兼董事会成员。库马尔博士还曾担任我们子公司EidosTherapeutics，Inc.的首席执行官。纳斯达克股票代码:EIDX，一家临床阶段生物制药公司，自2016年3月起担任EIDOS Therapeutics’；董事会成员。在此之前，他担任Myokardia，Inc.业务发展临时Vice President。纳斯达克股票代码:MYOK，一家临床阶段生物制药公司，从2012年到2014年。在此之前，Kumar博士从2011年到2014年担任Third Rock Ventures（一家风险投资公司）的负责人。加入Third Rock Ventures公司之前，他曾担任McKinsey&Company（全球管理咨询公司）的副校长（从2007年到2011年）。他在斯坦福大学（Stanford University）获得化学工程学士学位和硕士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学工程博士学位。
Neil Kumar,served as BBOT's Chief Executive Officer and President from August 2016 to April 2024. He is a co-founder and has been the Chief Executive Officer and a member of the board of directors of BridgeBio Pharma (Nasdaq: BBIO) since April 2015. Dr. Kumar has also served as the Chief Executive Officer of BridgeBio Pharma's subsidiary, Eidos Therapeutics, Inc. (formerly Nasdaq: EIDX), and a member of its board of directors since March 2016. Prior to co-founding BridgeBio Pharma, he was the interim Vice President of Business Development at MyoKardia, Inc. (formerly Nasdaq: MYOK, acquired by Bristol Myers Squibb), from 2012 to 2014. He was a principal at Third Rock Ventures from 2011 to 2014 and an associate principal at McKinsey & Company from 2007 to 2011. Dr. Kumar has served on the board of directors of LianBio (formerly Nasdaq: LIAN) since October 2019. He received his B.S. and M.S. degrees in Chemical Engineering from Stanford University and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology. - Neil Kumar是我们的联合创始人，自2015年4月起担任我们的首席执行官兼董事会成员。库马尔博士还曾担任我们子公司EidosTherapeutics，Inc.的首席执行官。纳斯达克股票代码:EIDX，一家临床阶段生物制药公司，自2016年3月起担任EIDOS Therapeutics’；董事会成员。在此之前，他担任Myokardia，Inc.业务发展临时Vice President。纳斯达克股票代码:MYOK，一家临床阶段生物制药公司，从2012年到2014年。在此之前，Kumar博士从2011年到2014年担任Third Rock Ventures（一家风险投资公司）的负责人。加入Third Rock Ventures公司之前，他曾担任McKinsey&Company（全球管理咨询公司）的副校长（从2007年到2011年）。他在斯坦福大学（Stanford University）获得化学工程学士学位和硕士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学工程博士学位。
- Neil Kumar,served as BBOT's Chief Executive Officer and President from August 2016 to April 2024. He is a co-founder and has been the Chief Executive Officer and a member of the board of directors of BridgeBio Pharma (Nasdaq: BBIO) since April 2015. Dr. Kumar has also served as the Chief Executive Officer of BridgeBio Pharma's subsidiary, Eidos Therapeutics, Inc. (formerly Nasdaq: EIDX), and a member of its board of directors since March 2016. Prior to co-founding BridgeBio Pharma, he was the interim Vice President of Business Development at MyoKardia, Inc. (formerly Nasdaq: MYOK, acquired by Bristol Myers Squibb), from 2012 to 2014. He was a principal at Third Rock Ventures from 2011 to 2014 and an associate principal at McKinsey & Company from 2007 to 2011. Dr. Kumar has served on the board of directors of LianBio (formerly Nasdaq: LIAN) since October 2019. He received his B.S. and M.S. degrees in Chemical Engineering from Stanford University and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
- Ali Satvat
-
Ali Satvat自2018年12月以来一直担任我们的董事会成员。Satvat先生加入Kohlberg Kravis Roberts&Co.。他于2012年1月加入全球投资公司L.P.及其附属公司“；KKR”；，是KKR’；的美洲私募股权平台医疗保健行业团队的合伙人兼联席主管，他是该平台投资委员会和投资组合管理委员会的成员。Satvat先生也是KKR&8217；的医疗保健战略增长平台的全球主管，他担任该平台的投资委员会和投资组合管理委员会的主席。萨特瓦特先生自2016年3月起担任生物制药公司BridgeBioPharma，Inc.的董事会成员，自2014年5月起担任生物制药公司Coherus生物科技有限公司的董事会成员，自2018年6月至2021年1月PRA HealthSciences，Inc.担任生物制药公司EidosTherapeutics，Inc.的董事会成员，一家全球合同研究组织，从2013年9月至2018年4月以及多家私人控股公司。加入KKR公司之前，他曾担任Apax Partners公司的负责人，在那里他曾投资于医疗保健（从2006年到2012年）。在此之前，Satvat先生曾在强生公司开发公司、Audax集团和黑石集团担任多个职位。Satvat先生拥有哈佛学院（Harvard College）历史与科学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）医疗保健管理与创业管理工商管理硕士学位。Satvat先生曾担任梦百合私人股本协会董事会成员。
Ali Satvat has served as a member of our board of directors since December 2018. Mr. Satvat joined Kohlberg Kravis Roberts & Co. L.P., a global investment firm together with its affiliates, “KKR”, in January 2012 and is a Partner and Co-Head of the Health Care industry team within KKR’s Americas Private Equity platform, for which he is a member of the Investment Committee and the Portfolio Management Committee. Mr. Satvat is also Global Head of KKR’s Health Care Strategic Growth platform, for which he chairs the Investment Committee and the Portfolio Management Committee. Mr. Satvat has served as a member of the boards of directors of BridgeBio Pharma, Inc., a biopharmaceutical company, since March 2016 Coherus BioSciences, Inc., a biopharmaceutical company, since May 2014 Eidos Therapeutics, Inc., a biopharmaceutical company, from June 2018 through January 2021 PRA Health Sciences, Inc., a global contract research organization, from September 2013 through April 2018 and multiple privately held companies. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners, where he invested in health care from 2006 to 2012. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group, and The Blackstone Group. Mr. Satvat holds an A.B. in History and Science from Harvard College and a M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat previously served as a member of the board of directors of the Healthcare Private Equity Association. - Ali Satvat自2018年12月以来一直担任我们的董事会成员。Satvat先生加入Kohlberg Kravis Roberts&Co.。他于2012年1月加入全球投资公司L.P.及其附属公司“；KKR”；，是KKR’；的美洲私募股权平台医疗保健行业团队的合伙人兼联席主管，他是该平台投资委员会和投资组合管理委员会的成员。Satvat先生也是KKR&8217；的医疗保健战略增长平台的全球主管，他担任该平台的投资委员会和投资组合管理委员会的主席。萨特瓦特先生自2016年3月起担任生物制药公司BridgeBioPharma，Inc.的董事会成员，自2014年5月起担任生物制药公司Coherus生物科技有限公司的董事会成员，自2018年6月至2021年1月PRA HealthSciences，Inc.担任生物制药公司EidosTherapeutics，Inc.的董事会成员，一家全球合同研究组织，从2013年9月至2018年4月以及多家私人控股公司。加入KKR公司之前，他曾担任Apax Partners公司的负责人，在那里他曾投资于医疗保健（从2006年到2012年）。在此之前，Satvat先生曾在强生公司开发公司、Audax集团和黑石集团担任多个职位。Satvat先生拥有哈佛学院（Harvard College）历史与科学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）医疗保健管理与创业管理工商管理硕士学位。Satvat先生曾担任梦百合私人股本协会董事会成员。
- Ali Satvat has served as a member of our board of directors since December 2018. Mr. Satvat joined Kohlberg Kravis Roberts & Co. L.P., a global investment firm together with its affiliates, “KKR”, in January 2012 and is a Partner and Co-Head of the Health Care industry team within KKR’s Americas Private Equity platform, for which he is a member of the Investment Committee and the Portfolio Management Committee. Mr. Satvat is also Global Head of KKR’s Health Care Strategic Growth platform, for which he chairs the Investment Committee and the Portfolio Management Committee. Mr. Satvat has served as a member of the boards of directors of BridgeBio Pharma, Inc., a biopharmaceutical company, since March 2016 Coherus BioSciences, Inc., a biopharmaceutical company, since May 2014 Eidos Therapeutics, Inc., a biopharmaceutical company, from June 2018 through January 2021 PRA Health Sciences, Inc., a global contract research organization, from September 2013 through April 2018 and multiple privately held companies. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners, where he invested in health care from 2006 to 2012. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group, and The Blackstone Group. Mr. Satvat holds an A.B. in History and Science from Harvard College and a M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat previously served as a member of the board of directors of the Healthcare Private Equity Association.
- Hoyoung Huh
-
Hoyoung Huh，2011年9月以来担任董事会主席，2011年2月到2011年9月担任执行董事长。2010年5月以来，担任Geron董事。他是一家新兴的医疗技术公司Cytomx Therapeutics的董事会主席。Huh博士也是一家制药开发公司ADDEX Pharmaceuticals，和一家糖尿病市场开发新型药物的生物制药公司AntriaBio的董事。2008年2月到2011年11月，Huh博士是一家专注于在心脏病、肿瘤、中枢神经系统疾病、代谢性疾病、眼科和疫苗方面开发治疗方法的全球制药Sanofi-Aventis全资所有的子公司BiPar Sciences的董事会主席，2009年BiPar和Sanofi-Aventis，整合，2008年2月到2009年12月，也担任BiPar的总裁和首席执行官。此外，Huh博士担任几个私营公司的董事会成员。Huh博士2009年9月到2010年4月，担任一家致力于发现、开发、制造和营销药品和医疗产品，包括营养品、设备和诊断的全球潜力健康医疗公司雅培全资子公司Facet Biotech的董事会成员。2008年2月到2009年5月，他是一家为肿瘤学、疼痛、抗感染、抗病毒和免疫学做准备，开发小分子药品、缩氨酸和其它生物技术药品，处于临床阶段的生物制药公司Nektar Therapeutics的董事会成员。2005年3月到2008年2月，Huh博士担任Nektar的首席运营官以及商业开发和营销的高级副总裁，在那里，他负责公司全球业务开发、营销和制造，领导Nektar的聚乙二醇化项目。在加入Nektar之前，Huh博士是一家全球管理咨询公司McKinsey & Company的合伙人，在那里，他负责生物技术和生物制药部门。在加入McKinsey之前，他在康乃尔大学医学院和Sloan-Kettering癌症中心担任医生和研究员。Huh博士拥有达特茅斯学院生物化学学士学位，以及康乃尔大学医学院遗传学和细胞生物学以及Sloan-Kettering协会的医学博士和博士学位。
Hoyoung Huh has served as Chairman of Akari Therapeutics, Plc's board of directors since November 2024, following Akari Therapeutics, Plc's merger with Peak Bio, Inc. Dr. Huh is the founder of Peak Bio Inc. (f/k/a pH Pharma) and has held positions of Chief Executive Officer and Board Chairman since founding pH Pharma in 2015. Dr. Huh is a Silicon Valley based entrepreneur and investor in healthcare and technology based businesses and has served as Lead Director of Pliant Therapeutics since December 2017. Dr. Huh has been involved in the formation and management of multiple biotechnology and innovation based companies, including holding board positions. He previously served as the Chairman of the board of directors of Geron Corporation from September 2011 to December 2018 and CytomX Therapeutics, Inc. from February 2012 to December 2018 and served as a member of the board of directors of Rezolute, Inc. (f/k/a AntriaBio, Inc.) from 2013 to January 2019. He holds an A.B. in Biochemistry from Dartmouth College, an M.D. from Cornell University Medical College and a Ph.D. in Cell Biology and Genetics from Cornell University Sloan Kettering Institute. - Hoyoung Huh，2011年9月以来担任董事会主席，2011年2月到2011年9月担任执行董事长。2010年5月以来，担任Geron董事。他是一家新兴的医疗技术公司Cytomx Therapeutics的董事会主席。Huh博士也是一家制药开发公司ADDEX Pharmaceuticals，和一家糖尿病市场开发新型药物的生物制药公司AntriaBio的董事。2008年2月到2011年11月，Huh博士是一家专注于在心脏病、肿瘤、中枢神经系统疾病、代谢性疾病、眼科和疫苗方面开发治疗方法的全球制药Sanofi-Aventis全资所有的子公司BiPar Sciences的董事会主席，2009年BiPar和Sanofi-Aventis，整合，2008年2月到2009年12月，也担任BiPar的总裁和首席执行官。此外，Huh博士担任几个私营公司的董事会成员。Huh博士2009年9月到2010年4月，担任一家致力于发现、开发、制造和营销药品和医疗产品，包括营养品、设备和诊断的全球潜力健康医疗公司雅培全资子公司Facet Biotech的董事会成员。2008年2月到2009年5月，他是一家为肿瘤学、疼痛、抗感染、抗病毒和免疫学做准备，开发小分子药品、缩氨酸和其它生物技术药品，处于临床阶段的生物制药公司Nektar Therapeutics的董事会成员。2005年3月到2008年2月，Huh博士担任Nektar的首席运营官以及商业开发和营销的高级副总裁，在那里，他负责公司全球业务开发、营销和制造，领导Nektar的聚乙二醇化项目。在加入Nektar之前，Huh博士是一家全球管理咨询公司McKinsey & Company的合伙人，在那里，他负责生物技术和生物制药部门。在加入McKinsey之前，他在康乃尔大学医学院和Sloan-Kettering癌症中心担任医生和研究员。Huh博士拥有达特茅斯学院生物化学学士学位，以及康乃尔大学医学院遗传学和细胞生物学以及Sloan-Kettering协会的医学博士和博士学位。
- Hoyoung Huh has served as Chairman of Akari Therapeutics, Plc's board of directors since November 2024, following Akari Therapeutics, Plc's merger with Peak Bio, Inc. Dr. Huh is the founder of Peak Bio Inc. (f/k/a pH Pharma) and has held positions of Chief Executive Officer and Board Chairman since founding pH Pharma in 2015. Dr. Huh is a Silicon Valley based entrepreneur and investor in healthcare and technology based businesses and has served as Lead Director of Pliant Therapeutics since December 2017. Dr. Huh has been involved in the formation and management of multiple biotechnology and innovation based companies, including holding board positions. He previously served as the Chairman of the board of directors of Geron Corporation from September 2011 to December 2018 and CytomX Therapeutics, Inc. from February 2012 to December 2018 and served as a member of the board of directors of Rezolute, Inc. (f/k/a AntriaBio, Inc.) from 2013 to January 2019. He holds an A.B. in Biochemistry from Dartmouth College, an M.D. from Cornell University Medical College and a Ph.D. in Cell Biology and Genetics from Cornell University Sloan Kettering Institute.
高管简历
中英对照 | 中文 | 英文- Jonathan C. Fox
Jonathan C. Fox，2013年3月起担任本公司首席医疗官。此前，于2006年11月-2012年7月期间，担任阿斯利康（AstraZeneca）的临床发展副总裁；此前，2004年1月-2006年11月期间担任AstraZeneca执行董事，负责心血管疾病、代谢及胃肠道的产品组合。此前，他曾在Merck & Co。担任临床心血管研究高级总监，以及GlaxoSmithKline plc。担任临床药理总监。他曾是Pennsylvania大学医学院20年的临床医学教授；此前曾监督血管生物学基础研究实验室。他目前在Stanford大学心血管病研究所担任顾问教授，担任洛杉矶California大学创新、技术和联盟顾问；以及是PA州温尼伍德Lankenau医学研究研究所的一个长期受托人。他还曾在美国FDA（Food and Drug Administration）心血管和肾脏药物产品咨询委员会担任四年的行业代表。他持有Chicago大学的学士、博士和医学硕士学位。以及完成了Duke大学的内科和心脏科研究生课程。
Jonathan C. Fox has served as our President and Chief Medical Officer since October 2016. Dr. Fox has served as the TA lead of cardiovascular and renal diseases at BridgeBio Pharma, LLC since October 2016. Prior to that, from March 2013 to September 2016 Dr. Fox served as the chief medical officer of MyoKardia, Inc. and as a senior advisor from October 2016 to March 2017. He worked as a consultant at Nigel-Montgomery, LLC from August 2012 to March 2013 and held various senior positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca LP from 1998 to 2012. He was on the faculty of the University of Pennsylvania School of Medicine from 1993 to 2013. He currently holds an adjunct faculty position at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in medicine and pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases, and is a Fellow of the American College of Cardiology.- Jonathan C. Fox，2013年3月起担任本公司首席医疗官。此前，于2006年11月-2012年7月期间，担任阿斯利康（AstraZeneca）的临床发展副总裁；此前，2004年1月-2006年11月期间担任AstraZeneca执行董事，负责心血管疾病、代谢及胃肠道的产品组合。此前，他曾在Merck & Co。担任临床心血管研究高级总监，以及GlaxoSmithKline plc。担任临床药理总监。他曾是Pennsylvania大学医学院20年的临床医学教授；此前曾监督血管生物学基础研究实验室。他目前在Stanford大学心血管病研究所担任顾问教授，担任洛杉矶California大学创新、技术和联盟顾问；以及是PA州温尼伍德Lankenau医学研究研究所的一个长期受托人。他还曾在美国FDA（Food and Drug Administration）心血管和肾脏药物产品咨询委员会担任四年的行业代表。他持有Chicago大学的学士、博士和医学硕士学位。以及完成了Duke大学的内科和心脏科研究生课程。
- Jonathan C. Fox has served as our President and Chief Medical Officer since October 2016. Dr. Fox has served as the TA lead of cardiovascular and renal diseases at BridgeBio Pharma, LLC since October 2016. Prior to that, from March 2013 to September 2016 Dr. Fox served as the chief medical officer of MyoKardia, Inc. and as a senior advisor from October 2016 to March 2017. He worked as a consultant at Nigel-Montgomery, LLC from August 2012 to March 2013 and held various senior positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca LP from 1998 to 2012. He was on the faculty of the University of Pennsylvania School of Medicine from 1993 to 2013. He currently holds an adjunct faculty position at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in medicine and pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases, and is a Fellow of the American College of Cardiology.
- Neil Kumar
Neil Kumar是我们的联合创始人，自2015年4月起担任我们的首席执行官兼董事会成员。库马尔博士还曾担任我们子公司EidosTherapeutics，Inc.的首席执行官。纳斯达克股票代码:EIDX，一家临床阶段生物制药公司，自2016年3月起担任EIDOS Therapeutics’；董事会成员。在此之前，他担任Myokardia，Inc.业务发展临时Vice President。纳斯达克股票代码:MYOK，一家临床阶段生物制药公司，从2012年到2014年。在此之前，Kumar博士从2011年到2014年担任Third Rock Ventures（一家风险投资公司）的负责人。加入Third Rock Ventures公司之前，他曾担任McKinsey&Company（全球管理咨询公司）的副校长（从2007年到2011年）。他在斯坦福大学（Stanford University）获得化学工程学士学位和硕士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学工程博士学位。
Neil Kumar,served as BBOT's Chief Executive Officer and President from August 2016 to April 2024. He is a co-founder and has been the Chief Executive Officer and a member of the board of directors of BridgeBio Pharma (Nasdaq: BBIO) since April 2015. Dr. Kumar has also served as the Chief Executive Officer of BridgeBio Pharma's subsidiary, Eidos Therapeutics, Inc. (formerly Nasdaq: EIDX), and a member of its board of directors since March 2016. Prior to co-founding BridgeBio Pharma, he was the interim Vice President of Business Development at MyoKardia, Inc. (formerly Nasdaq: MYOK, acquired by Bristol Myers Squibb), from 2012 to 2014. He was a principal at Third Rock Ventures from 2011 to 2014 and an associate principal at McKinsey & Company from 2007 to 2011. Dr. Kumar has served on the board of directors of LianBio (formerly Nasdaq: LIAN) since October 2019. He received his B.S. and M.S. degrees in Chemical Engineering from Stanford University and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.- Neil Kumar是我们的联合创始人，自2015年4月起担任我们的首席执行官兼董事会成员。库马尔博士还曾担任我们子公司EidosTherapeutics，Inc.的首席执行官。纳斯达克股票代码:EIDX，一家临床阶段生物制药公司，自2016年3月起担任EIDOS Therapeutics’；董事会成员。在此之前，他担任Myokardia，Inc.业务发展临时Vice President。纳斯达克股票代码:MYOK，一家临床阶段生物制药公司，从2012年到2014年。在此之前，Kumar博士从2011年到2014年担任Third Rock Ventures（一家风险投资公司）的负责人。加入Third Rock Ventures公司之前，他曾担任McKinsey&Company（全球管理咨询公司）的副校长（从2007年到2011年）。他在斯坦福大学（Stanford University）获得化学工程学士学位和硕士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学工程博士学位。
- Neil Kumar,served as BBOT's Chief Executive Officer and President from August 2016 to April 2024. He is a co-founder and has been the Chief Executive Officer and a member of the board of directors of BridgeBio Pharma (Nasdaq: BBIO) since April 2015. Dr. Kumar has also served as the Chief Executive Officer of BridgeBio Pharma's subsidiary, Eidos Therapeutics, Inc. (formerly Nasdaq: EIDX), and a member of its board of directors since March 2016. Prior to co-founding BridgeBio Pharma, he was the interim Vice President of Business Development at MyoKardia, Inc. (formerly Nasdaq: MYOK, acquired by Bristol Myers Squibb), from 2012 to 2014. He was a principal at Third Rock Ventures from 2011 to 2014 and an associate principal at McKinsey & Company from 2007 to 2011. Dr. Kumar has served on the board of directors of LianBio (formerly Nasdaq: LIAN) since October 2019. He received his B.S. and M.S. degrees in Chemical Engineering from Stanford University and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
- Uma Sinha
Uma Sinha自2016年4月起担任首席科学官，并担任Bridgebio其他子公司的首席科学官，包括Eidos Therapeutics。在此之前，辛哈博士担任全球血液疗法公司的首席科学官。纳斯达克股票代码:GBT，一家临床阶段的生物制药公司，2014年至2015年，此前曾于2013年至2014年担任研究高级副总裁。她是PortolaPharmaceuticals，Inc.生物系主任Vice President。从2010年到2012年，PTLA是一家临床阶段的生物技术公司，从2004年到2010年，它是转化生物学的Vice President。此前，Sinha博士在生物制药公司Millennium Pharmaceuticals，Inc.和生物制药公司COR Therapeutics，Inc.担任高级研究职位。Sinha博士在乔治亚大学（University of Georgia）获得生物化学博士学位，并获得理学学士学位。Presidency College化学荣誉。
Uma Sinha has served as Chief Scientific Officer since April 2016 and serves as the chief scientific officer of other BridgeBio subsidiaries, including Eidos Therapeutics. Prior to that, Dr. Sinha served as chief scientific officer of Global Blood Therapeutics, Inc. Nasdaq: GBT, a clinical stage biopharmaceutical company, from 2014 to 2015 and previously as senior vice president of research from 2013 to 2014. She was vice president, head of biology at Portola Pharmaceuticals, Inc. Nasdaq: PTLA, a clinical stage biotechnology company, from 2010 to 2012 and was the vice president of translational biology from 2004 to 2010. Previously, Dr. Sinha held senior research positions at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, and COR Therapeutics, Inc., a biopharmaceutical company. Dr. Sinha received her Ph.D. in biochemistry from the University of Georgia and her B.Sc. with honors in chemistry from Presidency College.- Uma Sinha自2016年4月起担任首席科学官，并担任Bridgebio其他子公司的首席科学官，包括Eidos Therapeutics。在此之前，辛哈博士担任全球血液疗法公司的首席科学官。纳斯达克股票代码:GBT，一家临床阶段的生物制药公司，2014年至2015年，此前曾于2013年至2014年担任研究高级副总裁。她是PortolaPharmaceuticals，Inc.生物系主任Vice President。从2010年到2012年，PTLA是一家临床阶段的生物技术公司，从2004年到2010年，它是转化生物学的Vice President。此前，Sinha博士在生物制药公司Millennium Pharmaceuticals，Inc.和生物制药公司COR Therapeutics，Inc.担任高级研究职位。Sinha博士在乔治亚大学（University of Georgia）获得生物化学博士学位，并获得理学学士学位。Presidency College化学荣誉。
- Uma Sinha has served as Chief Scientific Officer since April 2016 and serves as the chief scientific officer of other BridgeBio subsidiaries, including Eidos Therapeutics. Prior to that, Dr. Sinha served as chief scientific officer of Global Blood Therapeutics, Inc. Nasdaq: GBT, a clinical stage biopharmaceutical company, from 2014 to 2015 and previously as senior vice president of research from 2013 to 2014. She was vice president, head of biology at Portola Pharmaceuticals, Inc. Nasdaq: PTLA, a clinical stage biotechnology company, from 2010 to 2012 and was the vice president of translational biology from 2004 to 2010. Previously, Dr. Sinha held senior research positions at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, and COR Therapeutics, Inc., a biopharmaceutical company. Dr. Sinha received her Ph.D. in biochemistry from the University of Georgia and her B.Sc. with honors in chemistry from Presidency College.
- Christine Siu
Christine Siu自2017年12月起担任我们的首席财务官。2016年至2017年，她担任Eidos的首席运营官。她还担任Bridgebio其他子公司的首席运营官。在此之前，萧女士于2014年至2017年担任治疗额颞痴呆症的Bluefield项目的首席商务官。在此之前，她曾于2012年至2014年担任全球血液疗法公司企业发展高级总监。她曾担任Third Rock Ventures公司的风险负责人（2011年至2012年）。此前，她曾担任Warburg Pincus and Thomas，McNerney&Partners公司（私人股本和风险投资公司）的职务，在那里她曾投资生命科学公司。她在密歇根大学（University of Michigan）获得细胞分子生物学和经济学学士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Christine Siu,has been a member of Monte Rosa Therapeutics, Inc. board of directors since December 2020. Ms. Siu has served as the Chief Executive Officer of ML Bio Solutions, an affiliate of BridgeBio Pharma Inc., a pharmaceutical company, since January 2022 and as Chief Executive Officer of Pancreative Sciences, a portfolio company of GondolaBio, LLC, a biopharma startup, since February 2025. She formerly served as the Chief Operating Officer in Residence of BridgeBio Pharma Inc., a pharmaceutical company, from January 2020 to January 2022 and as the Chief Financial Officer of Eidos Therapeutics, Inc., a biopharmaceutical company from December 2017 to December 2019 and previously as Chief Operating Officer of Eidos Therapeutics, Inc. from April 2016 to December 2017. Ms. Siu served as the Chief Business Officer of The Bluefield Project to Cure Frontotemporal Dementia from 2014 to 2017, and previously from 2012 to 2014 as Senior Director of Corporate Development at Global Blood Therapeutics, Inc., a biopharmaceutical company. Previously, she held positions at various private equity and venture capital firms, including Third Rock Ventures, LLC, Warburg Pincus LLC and Thomas, McNerney & Partners, LLC, where she invested in life sciences companies. Ms. Siu has served as a member of the board of directors of Bright Peak Therapeutics, Inc., a privately held biotechnology company, since June 2021. Ms. Siu received an M.B.A. from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan.- Christine Siu自2017年12月起担任我们的首席财务官。2016年至2017年，她担任Eidos的首席运营官。她还担任Bridgebio其他子公司的首席运营官。在此之前，萧女士于2014年至2017年担任治疗额颞痴呆症的Bluefield项目的首席商务官。在此之前，她曾于2012年至2014年担任全球血液疗法公司企业发展高级总监。她曾担任Third Rock Ventures公司的风险负责人（2011年至2012年）。此前，她曾担任Warburg Pincus and Thomas，McNerney&Partners公司（私人股本和风险投资公司）的职务，在那里她曾投资生命科学公司。她在密歇根大学（University of Michigan）获得细胞分子生物学和经济学学士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Christine Siu,has been a member of Monte Rosa Therapeutics, Inc. board of directors since December 2020. Ms. Siu has served as the Chief Executive Officer of ML Bio Solutions, an affiliate of BridgeBio Pharma Inc., a pharmaceutical company, since January 2022 and as Chief Executive Officer of Pancreative Sciences, a portfolio company of GondolaBio, LLC, a biopharma startup, since February 2025. She formerly served as the Chief Operating Officer in Residence of BridgeBio Pharma Inc., a pharmaceutical company, from January 2020 to January 2022 and as the Chief Financial Officer of Eidos Therapeutics, Inc., a biopharmaceutical company from December 2017 to December 2019 and previously as Chief Operating Officer of Eidos Therapeutics, Inc. from April 2016 to December 2017. Ms. Siu served as the Chief Business Officer of The Bluefield Project to Cure Frontotemporal Dementia from 2014 to 2017, and previously from 2012 to 2014 as Senior Director of Corporate Development at Global Blood Therapeutics, Inc., a biopharmaceutical company. Previously, she held positions at various private equity and venture capital firms, including Third Rock Ventures, LLC, Warburg Pincus LLC and Thomas, McNerney & Partners, LLC, where she invested in life sciences companies. Ms. Siu has served as a member of the board of directors of Bright Peak Therapeutics, Inc., a privately held biotechnology company, since June 2021. Ms. Siu received an M.B.A. from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan.